Clinical Validation: NaturaLip™ Sensitive Skin Safety Study
Study conducted by ALS Pharmaceutical, Beauty, and Personal Care — November 2025
At First Dose Cosmetics, every claim we make is backed by data. NaturaLip™ was formulated specifically for use on post-treatment skin — a context where sensitivity, inflammation, and barrier compromise are already present. That standard demanded independent clinical validation before we brought this product to market.
Here's what the study found.
The Study
NaturaLip™ underwent a 77-Subject Human Repeat Insult Patch Test (HRIPT) for sensitive skin, conducted independently by ALS Global — an FDA and DEA registered laboratory specializing in clinical efficacy, safety, and toxicology testing for personal care products.
The objective was to evaluate NaturaLip™ for both skin irritation potential and sensitization (contact allergy) potential under repeated exposure conditions, specifically among participants who self-identified as having sensitive skin.
The study ran from September 22 to October 31, 2025, and was overseen by a consulting dermatologist and a clinical quality assurance team.
Who Was Tested
77 subjects were enrolled. 54 completed the full study. All participants had self-perceived sensitive skin — the precise population that matters most for a post-treatment recovery product.
The panel reflected real-world diversity in age, skin type, and demographic profile:
- Age range: 18–65
- Fitzpatrick skin types II, III, and IV represented
- 41 female, 13 male participants completing the study
Subjects who did not complete the study were discontinued for reasons entirely unrelated to the product — including adhesive tape sensitivity from the patch delivery mechanism itself. No subjects were discontinued due to any reaction to NaturaLip™.
How It Was Tested
The HRIPT protocol is one of the most rigorous sensitive skin safety evaluations used in the cosmetics industry. It involves repeated patch application across a three-week induction phase — nine consecutive 48 to 72-hour exposures — followed by a 10-day rest period and a final challenge dose applied to a previously unexposed site.
Reactions were scored using the International Contact Dermatitis Research Group scale, from 0 (no reaction) through 4 (erythema, edema, papules, and vesicles). Evaluations were conducted by trained laboratory personnel who were blinded to treatment assignments and prior scores.
The Results
Every subject who completed the study recorded a score of 0 across all induction and challenge readings.
No irritation. No sensitization. No adverse reactions to NaturaLip™.
The consulting dermatologist, Maria Elisa Barbosa Bueno de Campos, MD, concluded that under the conditions of the study, NaturaLip™ showed no indication of potential to elicit dermal irritation or sensitization in individuals with sensitive skin.
What This Means for Post-Treatment Use
Lip filler procedures temporarily compromise the skin barrier. The 72-hour critical recovery period immediately following treatment is when the skin is at its most reactive — and most in need of a product it can trust.
NaturaLip™ was designed for exactly this window. This study confirms what the formulation was built to deliver: a recovery experience that is effective, gentle, and clinically validated safe for sensitive skin.
Study No. Panel 41 | Accession No. 1268870 | Conducted by ALS Global, Torrance, CA Full study documentation available upon request for medspa partners.
Share: